Capricor Therapeutics
Capricor Therapeutics' revenue fell 100.0% to $0 million in fiscal 2025. Free cash flow was −$73 million. The diluted share count rose 32.0%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Capricor Therapeutics does
Capricor Therapeutics is a biotechnology company developing cell-based and exosome-based treatments for Duchenne muscular dystrophy, a rare genetic disease that causes progressive muscle damage and early death. Exosomes are tiny packets that cells release to carry signals to other cells.
Its main candidate is deramiocel, a cell therapy made from cardiac cells taken from donated human hearts. It is meant to slow the disease by calming inflammation and scarring, in both heart and skeletal muscle. The company has asked the FDA to approve it, and the request is under review. The company also has an exosome platform that is still in early lab testing.
Capricor has no products approved for sale and so no product revenue. It has paid for its work by selling shares, through government grants and through payments from distribution and collaboration partners. If deramiocel is approved, it plans to sell it in the United States itself and may use partners in some other countries.
Its biggest risks, as it describes them
- Deramiocel is not yet approved, and the FDA may not approve it.
- It has no products for sale, so it depends on raising money to keep going.
- Its exosome technology is still in early research and may never become a product.
- It may not be able to raise enough funds and could have to drop some programs.
- A breakdown or breach of its computer systems, or those of its outside research partners.
Income statement
Capricor Therapeutics lost money in fiscal 2025: a net loss of $105 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 35 | 41 | 40 | 152 | 318 |
| Debt incl. finance leases | 0 | 0 | 0 | 0 | 0 |
| Net debt (negative means net cash) | −35 | −41 | −40 | −152 | −318 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Interest coverage | — | — | — | — | −35.5x |
| Current ratio | 8.8x | 1.8x | 1.6x | 7.8x | 9.0x |
| Quick ratio | 8.8x | 1.8x | 1.6x | 7.8x | 9.0x |
Cash flow
Projections
Project Capricor Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Capricor Therapeutics reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 2 of 8 | 2 of 8 | 3 of 8 |
| Rule of 40 | 779.9% | −196.4% | — |
| Altman Z'' | −8.76 | 6.08 | 6.86 |
| Accruals ratio | 6.1% | −0.4% | −13.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Fail | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Fail | Fail |
| F-score | 2 of 8 | 2 of 8 | 3 of 8 |
Compare
Put Capricor Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Capricor Therapeutics | FY25 | −100.0% | — | — | — | — | 3 | |
| AbbVie | FY25 | 8.6% | 24.6% | 29.1% | 15.7% | 2.7x | 7 | Compare |
| Absci | FY25 | −38.2% | −4,297.0% | −3,358.3% | −162.8% | — | 3 | Compare |
| Arbutus Biopharma | FY25 | 128.2% | −271.0% | −281.4% | — | — | 3 | Compare |
| ADMA Biologics | FY25 | 19.6% | 37.5% | 5.5% | 39.5% | −0.1x | 5 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 4 | 3 | 2 | 1 | 0 | 0 | 3 | 25 | 22 | 0 |
| Revenue growth | −27.5% | −33.3% | −37.3% | −39.9% | −69.1% | −21.1% | 941.9% | 886.8% | −11.6% | −100.0% |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 16 | 11 | 12 | 5 | 8 | 14 | 22 | 36 | 50 | 84 |
| Operating income | −17 | −13 | −15 | −8 | −14 | −21 | −30 | −24 | −43 | −108 |
| Net income | −19 | 2 | −15 | −8 | −14 | −20 | −29 | −22 | −40 | −105 |
| Diluted EPS (US$) | −10.10 | 0.90 | −0.52 | −2.06 | −0.88 | −0.87 | −1.18 | −0.83 | −1.15 | −2.26 |
| Diluted shares (millions) | 2 | 3 | 3 | 4 | 16 | 23 | 25 | 27 | 35 | 46 |
| Cash flow | ||||||||||
| Cash from operations | −14 | −14 | −14 | −7 | −10 | −17 | 5 | −26 | −40 | −70 |
| Capital expenditure | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 1 | 3 |
| Free cash flow | −15 | −14 | −14 | −7 | −11 | −18 | 3 | −27 | −41 | −73 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 2 | 2 | 2 | 1 | 2 | 3 | 4 | 7 | 10 | 17 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 16 | 14 | 7 | 10 | — | 35 | 41 | 40 | 152 | 318 |
| Debt incl. finance leases | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Total assets | 19 | 16 | 9 | 11 | 35 | 41 | 50 | 59 | 170 | 356 |
| Total liabilities | 23 | 5 | 5 | 4 | 6 | 10 | 38 | 36 | 25 | 50 |
| Shareholders' equity | −4 | 11 | 5 | 7 | 28 | 31 | 12 | 23 | 146 | 306 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | −424.6% | −482.4% | −917.0% | −769.5% | −4,412.6% | −8,549.9% | −1,163.9% | −95.6% | −191.1% | — |
| Net margin | −470.3% | 91.2% | −908.9% | −760.4% | −4,401.9% | −8,175.9% | −1,137.4% | −88.5% | −181.7% | — |
| Free cash flow margin | −366.3% | −534.9% | −848.4% | −678.7% | −3,417.4% | −7,352.3% | 114.3% | −106.9% | −184.8% | — |
| Rule of 40 (growth + FCF margin) | −393.8% | −568.2% | −885.7% | −718.6% | −3,486.5% | −7,373.4% | 1,056.2% | 779.9% | −196.4% | — |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | — | 67.3% | −191.8% | −133.4% | −78.0% | −67.2% | −134.5% | −129.6% | −48.2% | −46.6% |
| Return on assets | −108.0% | 13.9% | −119.0% | −75.1% | −59.7% | −52.7% | −63.5% | −41.0% | −35.3% | −39.9% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |